PE20190661A1 - Preparacion de derivados del factor xa - Google Patents
Preparacion de derivados del factor xaInfo
- Publication number
- PE20190661A1 PE20190661A1 PE2018003241A PE2018003241A PE20190661A1 PE 20190661 A1 PE20190661 A1 PE 20190661A1 PE 2018003241 A PE2018003241 A PE 2018003241A PE 2018003241 A PE2018003241 A PE 2018003241A PE 20190661 A1 PE20190661 A1 PE 20190661A1
- Authority
- PE
- Peru
- Prior art keywords
- sample
- polypeptide
- acid sequence
- eluting
- loading
- Prior art date
Links
- 108010074860 Factor Xa Proteins 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000000523 sample Substances 0.000 abstract 7
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000012149 elution buffer Substances 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 101710162629 Trypsin inhibitor Proteins 0.000 abstract 1
- 229940122618 Trypsin inhibitor Drugs 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000005342 ion exchange Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000012521 purified sample Substances 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000002753 trypsin inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351841P | 2016-06-17 | 2016-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190661A1 true PE20190661A1 (es) | 2019-05-08 |
Family
ID=60663351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018003241A PE20190661A1 (es) | 2016-06-17 | 2017-06-19 | Preparacion de derivados del factor xa |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10604748B2 (enExample) |
| EP (3) | EP3926044B1 (enExample) |
| JP (4) | JP6959268B2 (enExample) |
| KR (1) | KR102373215B1 (enExample) |
| CN (3) | CN110167575B (enExample) |
| AU (3) | AU2017283720C1 (enExample) |
| CL (2) | CL2018003654A1 (enExample) |
| CO (1) | CO2019000120A2 (enExample) |
| DK (1) | DK3472314T3 (enExample) |
| EA (1) | EA037815B1 (enExample) |
| ES (2) | ES2875538T3 (enExample) |
| HU (1) | HUE054597T2 (enExample) |
| IL (1) | IL263591B2 (enExample) |
| MX (1) | MX2018015873A (enExample) |
| PE (1) | PE20190661A1 (enExample) |
| PH (1) | PH12018502614A1 (enExample) |
| PL (1) | PL3472314T3 (enExample) |
| PT (1) | PT3472314T (enExample) |
| SG (1) | SG11201810915QA (enExample) |
| SI (1) | SI3472314T1 (enExample) |
| WO (1) | WO2017219034A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3604510T3 (pl) * | 2009-03-30 | 2025-07-28 | Alexion Pharmaceuticals, Inc. | Antidota na inhibitory czynnika xa i sposoby ich stosowania |
| EP2948168B1 (en) * | 2013-01-24 | 2018-07-18 | Portola Pharmaceuticals, Inc. | Inhibition of tissue factor pathway inhibitor with factor xa derivatives |
| EP3926044B1 (en) * | 2016-06-17 | 2025-06-04 | Alexion Pharmaceuticals, Inc. | Preparation of factor xa derivatives |
| US12195774B2 (en) | 2018-06-19 | 2025-01-14 | Alexion Pharmaceuticals, Inc. | Antidotes to factor XA inhibitors |
| KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189019A (en) | 1990-04-23 | 1993-02-23 | Merck & Co., Inc. | Antistasin derived anticoagulant protein |
| US5589571A (en) | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
| JPH1066572A (ja) * | 1996-08-29 | 1998-03-10 | Showa Sangyo Co Ltd | 高純度の大豆トリプシンインヒビターの製造方法 |
| WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| CN101304971B (zh) | 2005-11-08 | 2011-09-07 | 米伦纽姆医药公司 | Xa因子抑制剂n-(5-氯-2-吡啶基)-2-[[4-[(二甲氨基)亚氨基甲基]苯甲酰基]氨基]-5-甲氧基-苯甲酰胺的医药盐和多晶型 |
| KR102069498B1 (ko) | 2007-09-28 | 2020-01-23 | 포톨라 파마슈티컬스, 인코포레이티드 | 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법 |
| CA2743496C (en) | 2008-11-14 | 2018-03-27 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents |
| PL3604510T3 (pl) * | 2009-03-30 | 2025-07-28 | Alexion Pharmaceuticals, Inc. | Antidota na inhibitory czynnika xa i sposoby ich stosowania |
| EP2453910B1 (en) | 2009-07-15 | 2016-08-31 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding |
| EP2861614B1 (en) * | 2012-06-14 | 2016-11-30 | Portola Pharmaceuticals, Inc. | METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES |
| US20140346397A1 (en) * | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
| EP2948168B1 (en) * | 2013-01-24 | 2018-07-18 | Portola Pharmaceuticals, Inc. | Inhibition of tissue factor pathway inhibitor with factor xa derivatives |
| CN112195169A (zh) * | 2013-09-24 | 2021-01-08 | 辉瑞大药厂 | 包含重组人凝血因子Xa蛋白的异质性群体的组合物 |
| KR20250150675A (ko) * | 2014-08-20 | 2025-10-20 | 포톨라 파마슈티컬스, 인코포레이티드 | 인자 xa 해독제용 동결건조된 제형 |
| EP3926044B1 (en) * | 2016-06-17 | 2025-06-04 | Alexion Pharmaceuticals, Inc. | Preparation of factor xa derivatives |
-
2017
- 2017-06-19 EP EP21164923.1A patent/EP3926044B1/en active Active
- 2017-06-19 ES ES17814267T patent/ES2875538T3/es active Active
- 2017-06-19 PL PL17814267T patent/PL3472314T3/pl unknown
- 2017-06-19 EP EP25172582.6A patent/EP4588932A3/en active Pending
- 2017-06-19 SI SI201730865T patent/SI3472314T1/sl unknown
- 2017-06-19 SG SG11201810915QA patent/SG11201810915QA/en unknown
- 2017-06-19 WO PCT/US2017/038169 patent/WO2017219034A2/en not_active Ceased
- 2017-06-19 JP JP2018565888A patent/JP6959268B2/ja active Active
- 2017-06-19 PE PE2018003241A patent/PE20190661A1/es unknown
- 2017-06-19 CN CN201780041530.2A patent/CN110167575B/zh active Active
- 2017-06-19 KR KR1020197000840A patent/KR102373215B1/ko active Active
- 2017-06-19 HU HUE17814267A patent/HUE054597T2/hu unknown
- 2017-06-19 PT PT178142675T patent/PT3472314T/pt unknown
- 2017-06-19 EA EA201990052A patent/EA037815B1/ru not_active IP Right Cessation
- 2017-06-19 ES ES21164923T patent/ES3038834T3/es active Active
- 2017-06-19 CN CN202310427500.2A patent/CN116425860B/zh active Active
- 2017-06-19 US US15/626,813 patent/US10604748B2/en active Active
- 2017-06-19 EP EP17814267.5A patent/EP3472314B1/en active Active
- 2017-06-19 IL IL263591A patent/IL263591B2/en unknown
- 2017-06-19 CN CN202410192888.7A patent/CN118271391A/zh active Pending
- 2017-06-19 DK DK17814267.5T patent/DK3472314T3/da active
- 2017-06-19 MX MX2018015873A patent/MX2018015873A/es unknown
- 2017-06-19 AU AU2017283720A patent/AU2017283720C1/en active Active
-
2018
- 2018-12-11 PH PH12018502614A patent/PH12018502614A1/en unknown
- 2018-12-17 CL CL2018003654A patent/CL2018003654A1/es unknown
-
2019
- 2019-01-09 CO CONC2019/0000120A patent/CO2019000120A2/es unknown
-
2020
- 2020-01-10 US US16/740,001 patent/US10954504B2/en active Active
- 2020-06-25 CL CL2020001733A patent/CL2020001733A1/es unknown
-
2021
- 2021-03-09 US US17/196,172 patent/US11845966B2/en active Active
- 2021-10-07 JP JP2021165271A patent/JP7273918B2/ja active Active
-
2023
- 2023-02-14 AU AU2023200825A patent/AU2023200825B2/en active Active
- 2023-04-28 JP JP2023074627A patent/JP2023086970A/ja active Pending
- 2023-11-08 US US18/505,022 patent/US20240076642A1/en active Pending
-
2025
- 2025-10-02 JP JP2025166337A patent/JP2026010692A/ja active Pending
-
2026
- 2026-07-20 AU AU2026206233A patent/AU2026206233A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025000172A (es) | Polipeptidos que contienen dominios d y sus usos | |
| BR112020024863A2 (pt) | Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso | |
| BR112017021308A2 (pt) | polipeptídeos contendo domínio de ligação de forma e uso dos mesmos | |
| EP4467650A3 (en) | Scaffold proteins | |
| ES2542853T3 (es) | Método para tratar miastenia grave | |
| PT1548032E (pt) | Péptidos kdr e vacinas que os contêm | |
| BR112017028205A2 (pt) | molécula de rna, vetor, célula hospedeira, composição farmacêutica, kit, e, uso de uma ou mais utrs. | |
| CL2019003408A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| PE20171111A1 (es) | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
| BR112017015567A2 (pt) | proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica | |
| EP3712165A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| WO2017024317A3 (en) | Methods to induce targeted protein degradation through bifunctional molecules | |
| MX2017010880A (es) | Variantes de polipéptidos para el clivaje de la toxina fusario, aditivo que contiene las mismas, uso de las mismas, y método para el clivaje de las toxinas fusario. | |
| BR112017026523A2 (pt) | vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado. | |
| MX392628B (es) | Amortiguador de lavado de cromatografia de afinidad. | |
| PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
| MX2018005399A (es) | Nuevo polipeptido con afinidad por pd-l1. | |
| CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
| BR112017020308A2 (pt) | udp-glicosiltransferases | |
| BR112017026142A2 (pt) | composições e métodos para tratar doença sprue celíaca | |
| BR112016011091A2 (pt) | sequência de endolisina kz144 modificada | |
| MX2022005644A (es) | Vectores vegetales, composiciones y usos relacionados con los mismos. | |
| BR112018073669A2 (pt) | proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso | |
| EA201691011A1 (ru) | Последовательность модифицированного эндолизина el188 | |
| CL2020002373A1 (es) | Composición de vacuna que comprende un péptido aislado de piojo de mar; uso de la vacuna para para prevenir o controlar una infestación de piojos de mar en un salmónido; vector; célula hospedadora (divisional de la solicitud no. 201900422). |